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Background: The combination of aclidinium bromide, a long-acting anticholinergic, and formoterol fumarate, a long-acting
beta2-agonist (400/12 μg twice daily) achieves improvements in lung function greater than either monotherapy in patients
with chronic obstructive pulmonary disease (COPD), and is approved in the European Union as a maintenance treatment.
The effect of this combination on symptoms of COPD and exacerbations is less well established. We examined
these outcomes in a pre-specified analysis of pooled data from two 24-week, double-blind, parallel-group,
active- and placebo-controlled, multicentre, randomised Phase III studies (ACLIFORM and AUGMENT).
Methods: Patients ≥40 years with moderate to severe COPD (post-bronchodilator forced expiratory volume in 1 s
[FEV1]/forced vital capacity <70 % and FEV1 ≥30 % but <80 % predicted normal) were randomised (ACLIFORM:
2:2:2:2:1; AUGMENT: 1:1:1:1:1) to twice-daily aclidinium/formoterol 400/12 μg or 400/6 μg, aclidinium 400 μg,
formoterol 12 μg or placebo via Genuair™/Pressair®. Dyspnoea (Transition Dyspnoea Index; TDI), daily symptoms
(EXAcerbations of Chronic pulmonary disease Tool [EXACT]-Respiratory Symptoms [E-RS] questionnaire), night-time
and early-morning symptoms, exacerbations (Healthcare Resource Utilisation [HCRU] and EXACT definitions) and
relief-medication use were assessed.
Results: The pooled intent-to-treat population included 3394 patients. Aclidinium/formoterol 400/12 μg significantly
improved TDI focal score versus placebo and both monotherapies at Week 24 (all p < 0.05). Over 24 weeks, significant
improvements in E-RS total score, overall night-time and early-morning symptom severity and limitation of early-
morning activities were observed with aclidinium/formoterol 400/12 μg versus placebo and both monotherapies
(all p < 0.05). The rate of moderate or severe HCRU exacerbations was significantly reduced with aclidinium/formoterol
400/12 μg compared with placebo (p < 0.05) but not monotherapies; the rate of EXACT-defined exacerbations was
significantly reduced with aclidinium/formoterol 400/12 μg versus placebo (p < 0.01) and aclidinium (p < 0.05).
Time to first HCRU or EXACT exacerbation was longer with aclidinium/formoterol 400/12 μg compared with
placebo (all p < 0.05) but not the monotherapies. Relief-medication use was reduced with aclidinium/formoterol
400/12 μg versus placebo and aclidinium (p < 0.01).
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Conclusions: Aclidinium/formoterol 400/12 μg significantly improves 24-hour symptom control compared with
placebo, aclidinium and formoterol in patients with moderate to severe COPD. Furthermore, aclidinium/formoterol
400/12 μg reduces the frequency of exacerbations compared with placebo.
Trial registration: NCT01462942 and NCT01437397 (ClinicalTrials.gov)
Keywords: Aclidinium bromide/formoterol fumarate, Chronic obstructive pulmonary disease, Fixed-dose
combination, SymptomsBackground
Patients with chronic obstructive pulmonary disease
(COPD) experience a range of troublesome symptoms,
including breathlessness (dyspnoea), cough and chest
tightness [1–3] and from time to time episodes of acute
worsening of symptoms, requiring a change in medica-
tion and even hospitalisation (exacerbations) [4]. These
exacerbations are associated with accelerated decline in
lung function [5–7], reduced health status (quality of
life) [8–10] and higher mortality rates [4, 7].
The symptoms of COPD are most severe during the
night and early morning [2]. Observational studies sug-
gest that approximately 40–81 % of patients experience
morning symptoms [11, 12] and 58–78 % of patients ex-
perience night-time disturbances or symptoms [3, 11, 12].
There are several potential consequences of these symp-
toms. Morning symptoms can be associated with limita-
tion of activities during the day, impaired health status
and increased risk of an exacerbation [12]. Night-time
symptoms disturb sleep and reduce sleep quality, and, in
the long term, may be associated with development or
worsening of cardiovascular disease, cognitive problems,
depression and increased mortality [1]. Reducing the
prevalence and severity of COPD symptoms during the
day and night, including the early morning, is an import-
ant goal of treatment.
The use of one or two long-acting bronchodilators is
recommended for patients in Global initiative for
chronic Obstructive Lung Disease (GOLD) groups B, C
and D [4], who are symptomatic and/or at higher risk of
COPD exacerbations based on their history over the pre-
vious year. Compared with single bronchodilators, com-
bining bronchodilators with complementary mechanisms
of action, such as a long-acting muscarinic antagonist
(LAMA) and a long-acting ß2-agonist (LABA), achieves
greater improvements in lung function than either bron-
chodilator given alone. Combining two bronchodilators in
one device has the potential to improve patient adherence
to treatment [13, 14] and may result in greater symptom
control. However, results of studies of symptom relief and
prevention of exacerbations with dual bronchodilators
compared with single bronchodilator use or placebo have
varied [15–19]. Effects on patient-reported outcomes
(PROs) have generally been lower than anticipated andthis may be due to a number of factors. PROs often ex-
hibit a large placebo response, which can make interpret-
ation of treatment effect difficult [20, 21]. In addition, it
may be difficult to observe significant treatment effects
with a dual bronchodilator versus its monotherapy com-
ponents, given that the added benefit of a second bron-
chodilator is likely to be much lower than that seen with a
single bronchodilator versus placebo [21].
A fixed-dose combination (FDC) of the LAMA, aclidi-
nium and the LABA, formoterol fumarate, 400/12 μg
twice daily (BID) has recently been approved in the
European Union as a maintenance bronchodilator for
patients with COPD [22]. Two pivotal, randomised,
placebo-controlled studies (ACLIFORM and AUGMENT)
of two different doses of aclidinium/formoterol FDC
(400/12 μg and 400/6 μg BID) have previously been re-
ported [23, 24]. In these studies, rapid and sustained
improvements in lung function were observed over
24 h, with significant improvements in bronchodilation
compared with placebo and the monotherapies across
six months. In both studies, the safety profiles of the
aclidinium/formoterol FDCs were similar to placebo
and the monotherapies, with no evidence for additive
adverse events (AEs) [23, 24]. The co-primary end-
points of both studies were 1-hour morning post-dose
forced expiratory volume in 1 s (FEV1) versus aclidi-
nium and morning pre-dose (trough) FEV1 versus for-
moterol. These and other pre-specified secondary and
additional endpoints, including patient-reported out-
comes, have been reported elsewhere [23, 24].
Here, we report results of a pre-specified pooled ana-
lysis of data from the two studies, which together are
powered to provide more reliable estimates of the effect
of aclidinium/formoterol FDC on symptoms and COPD
exacerbations compared not only with placebo, but also
the monotherapies, across a wide range of endpoints.




ACLIFORM and AUGMENT were Phase III, double-
blind, randomised, parallel-group, active- and placebo-
controlled multicentre studies, conducted at 193 centres
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tries in Europe) and 222 centres in 4 countries
(Australia, Canada, New Zealand and the USA), respect-
ively. Each study had a 2- to 3-week run-in period (dur-
ing which long-acting bronchodilator medications were
withdrawn) followed by a 24-week treatment period and
a follow-up visit two weeks after treatment concluded.
Patients were randomised in a 2:2:2:2:1 ratio in ACLI-
FORM and a 1:1:1:1:1 ratio in AUGMENT to receive
aclidinium/formoterol FDC 400/12 μg or 400/6 μg, acli-
dinium 400 μg, formoterol 12 μg or placebo (all BID) via
a multidose dry powder inhaler (Genuair™/Pressair®a;
AstraZeneca PLC, Barcelona, Spain).
The studies were conducted in accordance with the
Declaration of Helsinki, International Conference on
Harmonisation/Good Clinical Practice Guidelines and
local regulations. The protocols were approved by the
regulatory authorities in each country and the Institu-
tional Review Board or Independent Ethics Committee
at each study centre.
Study populations
Patients with stable COPD aged ≥40 years who were
current or former cigarette smokers (smoking history ≥10
pack-years) and diagnosed with moderate to severe airflow
obstruction (post-bronchodilator FEV1/forced vital cap-
acity <70 % and FEV1 ≥ 30 % and <80 % predicted) were
eligible for inclusion. Key exclusion criteria included
COPD exacerbation or respiratory tract infection ≤6 weeks
pre-screening (≤3 months if hospitalised), presence of
clinically significant respiratory disease other than
COPD or clinically significant cardiovascular conditions
(defined as myocardial infarction ≤6 months pre-
screening, unstable angina or unstable arrhythmia which
required changes in therapy within 12 months pre-
screening or newly-diagnosed arrhythmia ≤3 months pre-
screening, hospitalisation ≤12 months pre-screening for
heart failure functional class III or IV as per the New York
Heart Association guidelines). A COPD exacerbation in
the previous 12 months was not a requirement for
inclusion.
Inhaled salbutamol was permitted as relief medica-
tion; its use was discontinued 6 h prior to study visits.
Additional permitted medications included inhaled cor-
ticosteroids (ICS), oral or parenteral corticosteroids
(≤10 mg/day of prednisone or 20 mg every other day),
oral sustained-release theophylline and oxygen therapy
(<15 h/day), provided treatment was stable ≥4 weeks
pre-screening.
Study assessments and endpoints
Dyspnoea was assessed using the Baseline Dyspnoea
Index; changes were measured using the Transitional
Dyspnoea Index (TDI). TDI endpoints included TDIfocal score and a responder analysis quantifying re-
sponders and ‘deteriorators’ (percentage of patients with
improvements or worsenings of ≥1 unit [the minimum
clinically important difference, MCID]) at Weeks 4, 12
and 24.
Symptoms and relief-medication use were recorded
in an electronic patient diary. Daily COPD symptoms
were assessed using the EXAcerbations of Chronic pul-
monary disease Tool (EXACT)-Respiratory Symptoms
(E-RS) questionnaire (11 items from the 3 domains of
the 14-item EXACT questionnaire: breathlessness,
cough and sputum and chest symptoms) completed at
night [25, 26]. E-RS total scores range from 0 to 40,
with higher scores indicating more severe symptoms.
Changes from baseline in E-RS total score and breath-
lessness, cough and sputum and chest symptoms do-
main scores were assessed over 24 weeks. E-RS
responders were also analysed using the definition re-
cently proposed by Leidy and colleagues (percentage of
patients achieving a reduction in E-RS total score of ≥2
units) [27]. Night-time and early-morning symptoms
were recorded every morning using newly developed
questionnaires. The psychometric properties of these
questionnaires have been evaluated and final tools de-
veloped (the Early-Morning Symptoms of COPD Instru-
ment [EMSCI] and the Night-time Symptoms of COPD
Instrument [NiSCI]) [28, 29]. Scores ranged from 0 (no
symptoms) to 4 (very severe symptoms). The question-
naires also evaluated nocturnal awakenings and limita-
tion of early-morning activities (scores ranged from 0
[no limitation] to 4 [a very great deal]). Symptoms
assessed over 24 weeks included change from baseline
in the severity of night-time and early-morning cough,
wheezing, shortness of breath and difficulty bringing up
phlegm, overall night-time and early-morning symptom
severity, number of nocturnal awakenings and limita-
tion of early-morning activities due to COPD symp-
toms. Change from baseline in daily relief-medication
use over 24 weeks was also assessed using the patient
diary.
COPD exacerbations were assessed throughout the
study by the Healthcare Resource Utilisation (HCRU)
definition and the 14-item EXACT questionnaire [25].
An HCRU exacerbation was defined as an increase in
COPD symptoms during ≥2 consecutive days that re-
quired a change in COPD treatment, and an EXACT ex-
acerbation was defined as a persistent increase from
baseline in total EXACT score of ≥9 points for ≥3 days
or ≥12 points for ≥2 days. HCRU exacerbations were
categorised as mild (self-managed by the patient at home
by increasing usual COPD medication [short-acting
bronchodilator and/or ICS use]), moderate (not leading
to hospitalisation but treated with antibiotics and/or sys-
temic corticosteroids [or increase in dose of systemic
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[overnight stay or emergency room visit]). Exacerbation
endpoints were the rate of COPD exacerbation and time
to first COPD exacerbation.
TDI focal score versus placebo at Week 24 was a sec-
ondary endpoint in both studies; all other assessments
listed above were additional endpoints.
Statistical analyses
Data were analysed using SAS® Version 9.3. All efficacy
analyses were pre-specified, other than those of TDI
deteriorators, E-RS responders and data stratified by
GOLD group or concomitant ICS use. All analyses were
performed in the intent-to-treat (ITT) population (pa-
tients who had a baseline and ≥1 post-baseline FEV1
measurement and received ≥1 dose of the study medica-
tion), with the exception of exacerbations analyses,
which were performed in the ITT-exacerbations popula-
tion (that is, all randomised patients who received ≥1
dose of study medication).
TDI focal score and three dimension scores, E-RS total
score and domain scores, night-time and early-morning
symptom severity and relief-medication use were ana-
lysed by a mixed model for repeated measures, and TDI
responders/deteriorators and E-RS responders were ana-
lysed by a logistic random-effect model. These models
were adjusted by age and baseline values as covariates,
and treatment group, sex, smoking status, visit and treat-
ment group-by-visit interaction as fixed-effect factors.
Additionally, the logistic random-effect model had a ran-
dom intercept to account for the variability amongst pa-
tients. The rate of COPD exacerbations per patient per
year and time to first exacerbation were analysed by a
negative binomial regression model and a Cox propor-


























































Fig. 1 CONSORT diagram of patient flow in the pooled ACLIFORM and AU
reported in this paper and can be found elsewhere [23, 24]; AE, adverse evage as a covariate, and treatment group, sex, baseline
ICS use, baseline COPD severity and smoking status as
factors. In addition, TDI and exacerbations data were
stratified by concomitant ICS use (defined as any ICS
use at baseline [in the 15 days prior to study start] that
continued throughout the treatment period) and GOLD
group (based on airflow limitation, exacerbation risk and
SGRQ total score [a surrogate measure for the COPD
Assessment Test (CAT); an SGRQ total score ≥25 corre-
sponds with a CAT score ≥10 [30]]).
Results
Patient population
Of 3421 randomised patients, 3394 (99.2 %) were included
in the ITT population and 3398 (99.3 %) were included in
the ITT-exacerbations population. In total, 573 (16.7 %)
patients discontinued treatment; the primary reasons were
withdrawal of consent (4.5 %), AEs (4.2 %) and protocol
violation (3.2 %). Patient flow and the reasons for discon-
tinuation are presented by treatment group in Fig. 1. Pa-
tient demographics and baseline characteristics were
similar between the treatment groups (Table 1). The pa-
tient population was not enriched for exacerbations and
the number of exacerbations in the previous year was low
(0.3–0.5 exacerbations; Table 1). Overall, 1335 (39.3 %) pa-
tients in the ITT-exacerbations population were using ICS
at baseline. At baseline, 88.3 % and 94.4 % of patients re-
ported night-time and early-morning symptoms of COPD
(Table 2), although symptoms were relatively mild (rated
1.1–1.3 units out of a maximum score of 4; Table 1).
When the ITT population was stratified by GOLD group,
9.2, 45.9, 3.0 and 41.9 % of patients were in GOLD groups
A, B, C and D, respectively (75 patients were missing data
required for GOLD classification). Baseline GOLD data by



























































GMENT studies. Data for the 400/6 μg dose of the FDC are not
ent; FDC, aclidinium/formoterol fixed-dose combination
Table 1 Patient demographics and baseline characteristics for the pooled ACLIFORM and AUGMENT studies
FDC 400/12 μg (n = 720) Aclidinium 400 μg (n = 720) Formoterol 12 μg (n = 715) Placebo (n = 525)
Age, years 63.4 ± 8.5 63.7 ± 8.5 63.5 ± 8.2 63.7 ± 8.6
Gender, male, n (%) 429 (59.6) 442 (61.4) 423 (59.2) 313 (59.6)
Current smoker, n (%) 354 (49.2) 351 (48.8) 350 (49.0) 263 (50.1)
FEV1, L 1.4 ± 0.5 1.4 ± 0.5 1.4 ± 0.5 1.4 ± 0.6
Post-bronchodilator FEV1,
% predicted
53.9 ± 13.2 53.3 ± 13.1 54.2 ± 13.1 53.5 ± 13.4
Number of exacerbations in
previous 12 months
0.5 (0.9) 0.5 (0.8) 0.4 (0.8) 0.3 (0.7)
Prior COPD medicationa, n (%)
Any COPD medication 576 (80.0) 591 (82.1) 574 (80.3) 411 (78.3)
LABA + ICS 210 (29.2) 234 (32.5) 222 (31.0) 172 (32.8)
LAMA 209 (29.0) 190 (26.4) 181 (25.3) 141 (26.9)
ICS 114 (15.8) 106 (14.7) 96 (13.4) 62 (11.8)
LABA 85 (11.8) 81 (11.3) 92 (12.9) 42 (8.0)
BDI focal score 6.4 ± 2.1 6.5 ± 2.1 6.4 ± 2.2 6.5 ± 2.2
E-RS total scoreb 12.9 ± 6.8 12.5 ± 6.4 12.3 ± 6.6 12.2 ± 6.3
Overall night-time COPD symptom
severity scorec
1.1 ± 0.7 1.1 ± 0.7 1.1 ± 0.7 1.1 ± 0.7
Overall early-morning COPD
symptom severity scorec
1.3 ± 0.7 1.3 ± 0.7 1.2 ± 0.7 1.2 ± 0.6
GOLD group, n (%)
A 62 (8.8) 51 (7.3) 74 (10.6) 48 (9.4)
B 320 (45.5) 322 (46.0) 327 (46.7) 224 (43.7)
C 16 (2.3) 27 (3.9) 16 (2.3) 17 (3.3)
D 305 (43.4) 300 (42.9) 283 (40.4) 224 (43.7)
Data are presented as mean ± standard deviation for the pooled ITT population, unless otherwise stated
BDI Baseline Dyspnoea Index, COPD chronic obstructive pulmonary disease, E-RS EXAcerbations of Chronic obstructive pulmonary disease Tool (EXACT)-Respiratory
Symptoms questionnaire, FDC aclidinium/formoterol fixed-dose combination, FEV1 forced expiratory volume in 1 s, ICS inhaled corticosteroid, ITT intent-to-treat,
LABA long-acting β2-agonist, LAMA long-acting muscarinic antagonist
aPatients can be included in multiple categories
bE-RS total scores range from 0 to 40 with higher scores indicating more severe symptoms
cNight-time and early-morning symptom scores range from 0 (no symptoms) to 4 (very severe symptoms)
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FDC 400/12 μg significantly improved TDI focal score
versus placebo at all visits assessed, and these improve-
ments exceeded the MCID of 1 unit (range of least
squares [LS] means differences vs placebo: 1.32–1.43
units; all time points p < 0.001). Additionally, FDC 400/
12 μg significantly improved TDI focal score versus for-
moterol at all visits assessed (range of LS means differ-
ences vs formoterol: 0.47–0.63 units; all visits p < 0.01)
and versus aclidinium from Week 12 onwards (difference
vs aclidinium: 0.39–0.44 units; Week 12 and 24 p < 0.05;
Fig. 2a and b).
Overall, 61.9 % of patients achieved the MCID in
TDI focal score with FDC 400/12 μg compared with
55.7 % for aclidinium, 57.0 % for formoterol and
40.3 % for placebo. Treatment with FDC 400/12 μg
significantly increased the odds of improving by the
MCID in TDI versus placebo (Table 3), and significantlyreduced the odds of TDI worsening by the MCID
versus placebo (Table 3). There were no significant
differences in the odds of TDI improving or worsening
by the MCID with FDC 400/12 μg versus either
monotherapy.
When stratified by ICS use, FDC 400/12 μg significantly
improved TDI versus placebo regardless of concomitant
ICS use (LS mean difference vs placebo with ICS: 1.59
units, p < 0.001; without ICS: 1.36 units, p < 0.001). Sig-
nificant improvements in TDI with FDC 400/12 μg
versus the monotherapies were only observed in pa-
tients who were not using concomitant ICS (LS
mean difference vs aclidinium with ICS: 0.02 units,
p = 0.948; without ICS: 0.66, p = 0.002; LS mean dif-
ference vs formoterol with ICS: 0.45 units, p = 0.105;
without ICS: 0.48, p = 0.024).
Data for improvements in TDI at Week 24 stratified
by GOLD group are presented in Additional file 1.
Table 2 Prevalence of daytime, night-time and early-morning
symptoms at baseline





Shortness of breath 67.2






Shortness of breath 77.6
Difficulty bringing up phlegm 48.6
Limitation of early-morning activities 90.6
Data are for the pooled ITT population
ITT intent-to-treat
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Over 24 weeks, E-RS total score was significantly im-
proved with FDC 400/12 μg compared with placebo
and both monotherapies (mean change from baseline:
FDC 400/12 μg: −2.4 units [−18.6 %]; aclidinium: −1.8
units [−14.2 %]; formoterol: −1.8 units [−14.7 %];
placebo: –1.2 units [−10.0 %]; p < 0.001 vs placebo;
p < 0.01 vs both monotherapies; Additional file 1:
Figure S2). Overall, 48.7 % of patients had improve-
ments in E-RS total score that exceeded the recently
proposed MCID (percentage of patients achieving a re-
duction in E-RS total score of ≥2 units) [27] compared
with 41.3 % with aclidinium, 42.3 % with formoterol
and 34.4 % with placebo. Treatment with FDC 400/12 μg
significantly increased the odds of improving by the MCID
versus placebo (odds ratio [OR]: 1.9; p < 0.001) and
formoterol (OR: 1.3; p < 0.05) but not aclidinium (OR: 1.2;
p = 0.145). Improvements in E-RS domain scores are
described in an online supplement (Additional file 1).
Night-time and early-morning symptoms (NiSCI and
EMSCI)
Over 24 weeks, FDC 400/12 μg significantly improved
night-time and early-morning symptom severity com-
pared with placebo, including both overall and individual
symptom severity scores (cough, wheezing, shortness of
breath and difficulty bringing up phlegm; Fig. 3a and b).
Additionally, compared with placebo, FDC 400/12 μg
significantly improved limitation of activities due to
morning symptoms (Fig. 3b). FDC 400/12 μg had no sig-
nificant effect on nocturnal awakenings compared with
placebo (Fig. 3a).Although improvements in overall night-time symp-
tom severity were observed in all treatment arms, the
change from baseline was significantly greater with
FDC 400/12 μg compared with the monotherapies
(FDC 400/12 μg: −0.25 units [−21.6 %]; aclidinium
400 μg: –0.16 units [−14.5 %]; formoterol 12 μg: −0.19
units [−18.2 %]; p < 0.001 vs aclidinium and p < 0.05 vs
formoterol). A similar pattern was observed for im-
provements from baseline in overall early-morning symp-
tom severity (FDC 400/12 μg: −0.23 units [−17.0 %];
aclidinium 400 μg: −0.14 units [−10.7 %]; formoterol
12 μg: −0.17 units [−13.6 %]; p < 0.001 vs aclidinium and
p < 0.01 vs formoterol).
Changes in individual night-time and early-morning
symptoms (cough, wheezing, shortness of breath and diffi-
culty bringing up phlegm), limitation of early-morning ac-
tivities and nocturnal awakenings versus monotherapy are
described in an online supplement (Additional file 1).
COPD exacerbations
The rate of moderate or severe HCRU exacerbations
was significantly lower (−29 %) with FDC 400/12 μg
compared with placebo. The rate of HCRU exacerba-
tions of any severity was also lower (−24 %) with FDC
400/12 μg compared with placebo; however, the differ-
ences did not reach statistical significance (Fig. 4a). Add-
itionally, compared with placebo, FDC 400/12 μg
significantly increased the time to first exacerbation for
HCRU exacerbations of any severity, and also those that
were moderate or severe (Table 4). These results were
supported by the EXACT data, where higher rates of ex-
acerbations were observed (1.18–1.51 EXACT exacerba-
tions [any severity] compared with 0.36–0.47 HCRU
exacerbations [any severity] per patient per year across
treatment groups) and a similar pattern of reduction in
exacerbation rate (−22 %) and time to first exacerbation
was seen with FDC 400/12 μg versus placebo (Fig. 4b;
Table 4). Monotherapy data for rate of exacerbation and
time to first exacerbation are also shown in Fig. 4 and
Table 4, respectively.
Data for rate of exacerbations stratified by ICS use
are presented in Additional file 1. When HCRU or
EXACT exacerbations were stratified by concomitant
ICS use, patients with concomitant ICS use had higher
exacerbation rates compared with those who were not
using ICS (Additional file 1: Figure S4). The reduction
in rate of moderate to severe HCRU exacerbations and
HCRU exacerbations of any severity was significantly
greater with FDC 400/12 μg compared with placebo
in patients with concomitant ICS use but not those
without ICS; the comparisons versus the mono-
therapies did not reach significance in patients with
or without concomitant ICS use (Additional file 1:









































FDC 400/12 µg vs placebo
FDC 400/12 µg vs aclidinium 400 µg
FDC 400/12 µg vs formoterol 12 µg
Aclidinium 400 µg vs placebo




































Fig. 2 TDI focal score at Week 24 (a) and over 24 weeks (b). Data are LS means ± SE for the pooled ITT population; ***p < 0.001 vs placebo,
‡p < 0.05 vs aclidinium ††p < 0.01 vs formoterol; FDC, aclidinium/formoterol fixed-dose combination; ITT, intent-to-treat; LS, least squares;
MCID, minimum clinically important difference; ns, not significant; SE, standard error; TDI, Transitional Dyspnoea Index
Bateman et al. Respiratory Research  (2015) 16:92 Page 7 of 13exacerbations, although in addition, FDC 400/12 μg
significantly reduced the rate of EXACT exacerbations
compared with aclidinium 400 μg (Additional file 1:
Figure S4).
Data for exacerbation rates stratified by GOLD group
are presented in Additional file 1.Relief-medication use
Treatment with FDC 400/12 μg reduced overall daily
relief-medication use compared with placebo and the
monotherapies, although only the comparisons versus
placebo and aclidinium reached statistical significance(mean [CI]: FDC 400/12 μg: −1.73 [−1.88, −1.57] puffs/day;
aclidinium 400 μg: −1.37 [−1.52, −1.21] puffs/day; formo-
terol 12 μg: −1.52 [−1.68, −1.37] puffs/day; placebo: −0.82
[−1.00, −0.63] puffs/day; p < 0.001 vs placebo, p < 0.01
vs aclidinium).Discussion
This pooled analysis of the ACLIFORM and AUGMENT
studies showed that over six months, treatment with
aclidinium/formoterol FDC 400/12 μg led to reduced
breathlessness compared with placebo and both mono-
therapies in patients with moderate to severe COPD.















61.9 55.7 57.0 40.3
OR vs
placebo
2.8*** 2.1*** 2.2*** -
OR vs
aclidinium
1.3 - - -
OR vs
formoterol




7.8 9.3 10.9 15.8
OR vs
placebo
0.4*** 0.6** 0.7 -
OR vs
aclidinium
0.8 - - -
OR vs formoterol 0.7 - - -
Data are for the pooled ITT population; MCID for TDI is ≥1 unit
COPD chronic obstructive pulmonary disease, FDC aclidinium/formoterol
fixed-dose combination, ITT intent-to-treat, OR odds ratio, TDI Transition
Dyspnoea Index
***p < 0.001, **p < 0.01 vs placebo
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night-time and early-morning symptoms (overall NiSCI
and EMSCI symptom scores) were also observed versus
placebo and monotherapies. The FDC also significantly
reduced relief-medication use versus placebo and aclidi-
nium. The rate of exacerbations (moderate or severe
HCRU exacerbations and EXACT exacerbations of any
severity) was also significantly reduced compared with
placebo, but not the monotherapies, with the exception
of the rate of EXACT exacerbations, which was signifi-
cantly reduced with FDC 400/12 μg compared with acli-
dinium 400 μg.
These findings help to establish the clinical relevance
of the lung function improvements previously reported
from the ACLIFORM and AUGMENT studies, where
clinically and statistically significant improvements in
bronchodilation were observed with both aclidinium/for-
moterol FDC 400/12 μg and FDC 400/6 μg compared
with placebo and the monotherapies [23, 24]. Lung
function improvements were generally greater with
the 400/12 μg dose compared with the 400/6 μg dose
[23, 24]. This additive effect of dual bronchodilator use
has been reported in several studies with other broncho-
dilator combinations and is not surprising given
that LAMAs and LABAs have different modes of action
[15, 16]. However, there is less conclusive evidence that this
additional bronchodilation is associated with incremental
symptom benefits. The current pooled analysis provides
consistent evidence, using various different measurements,that this additional bronchodilation is associated with
symptomatic improvements.
In addition to aclidinium/formoterol 400/12 μg, two
other LAMA/LABA FDCs (umeclidinium/vilanterol
62.5/25 μg and indacaterol/glycopyrronium 110/50 μg)
are available for the treatment of COPD, and several
others are in clinical development [31–33]. In a
24-week clinical study, umeclidinium/vilanterol 62.5/25 μg
improved TDI focal score versus placebo but not ume-
clidinium or vilanterol monotherapy at Day 168 [16]. In
the SHINE study, indacaterol/glycopyrronium 110/50 μg
significantly improved TDI focal score versus tiotropium
but not indacaterol or glycopyrronium at Week 26 [15].
It is possible that with a larger dataset, some of the
treatment differences between the FDCs and their
monotherapy components may have reached statistical
significance in these studies. Our pooled analysis has
allowed us to examine a larger dataset and extends these
results by showing that a dual bronchodilator can provide
significantly greater improvements in TDI focal score
compared with both its LAMA and LABA monocompo-
nents. Demonstrating the benefit of the combination
drug over its monotherapy components for all end-
points is challenging, with most of the comparisons
falling short of the MCID for patient-reported out-
comes (TDI, SGRQ etc.) [15, 16]. Jones et al. recently
highlighted that most of our experience with MCIDs is
in the context of comparing an active treatment with
placebo, but when adding a second bronchodilator, the
additive benefit is likely to be smaller than that between
an active treatment and placebo [21]. For example, in
the present analysis, the difference in TDI with FDC
400/12 μg versus each of the monotherapies (0.4–0.5
units) was statistically significant but did not reach the
MCID. Jones et al. have proposed expressing these end-
points as a ‘minimum worthwhile incremental advan-
tage’; the percentage of patients who would experience
improvement at or above the MCID on adding one
treatment to another, or comparing two active treat-
ments [21]. In order to assess net benefit, the propor-
tion of patients who deteriorated by the MCID should
be reported in addition to the proportion of patients
who improved by the MCID, as we have done here. For
example, for TDI, approximately 30 % more patients expe-
rienced clinically meaningful benefits with the FDC com-
pared with placebo and approximately 8 % more patients
experienced clinically meaningful benefits with the FDC
compared with either monotherapy.
Dyspnoea is only one of a range of troublesome COPD
symptoms that can limit the patient’s ability to perform
daily tasks and lead to physical inactivity, social isolation
and impaired quality of life [4, 34]. Recently, the import-
ance of night-time and early-morning symptoms of COPD



















































































































































Fig. 3 Difference from placebo in change from baseline in symptom severity over 24 weeks. a Night-time symptoms; b early-morning symptoms;
Data are LS means differences from placebo ± 95 % CIs for the pooled ITT population; *p < 0.05, ***p < 0.001 vs placebo; aNocturnal awakenings
were the average number of awakenings per night. Other night-time symptoms were measured on a scale from 0 (no symptoms) to 4 (very se-
vere symptoms). Larger negative values indicate greater improvements in symptom severity; CI, confidence interval; FDC, aclidinium/formoterol
fixed-dose combination; ITT, intent-to-treat; LS, least squares
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and that these symptoms significantly reduce quality of life
[1, 3, 12]. In our pooled analysis, 89 and 94 % of patients
experienced night-time and early-morning symptoms at
baseline, respectively. This is slightly higher than previ-
ous estimates (morning symptoms: 40–81 %; night-time
disturbances or symptoms: 58–78 %) in patients with
similar airflow limitation (mean % predicted FEV1:
52.7–62.3) [3, 11, 12], although it is difficult to draw
comparisons given that different questionnaires wereemployed in each study. What is clear is that symptoms
are common amongst patients with COPD at these times
of day and our pooled analysis has provided good evidence
that aclidinium/formoterol 400/12 μg can improve overall
night-time and early-morning symptom severity com-
pared with placebo and both monotherapies.
It should be noted that in the present analysis, the
baseline night-time, early-morning and daily (E-RS)
symptom scores were relatively low compared with
other studies in patients with a similar degree of airflow
Fig. 4 Rate of COPD exacerbations based on HCRU (a) and EXACT
(b) definitions. Data are LS means and RR (CI) for the pooled
ITT-exacerbations population; *p < 0.05, **p < 0.01 vs placebo,
ǂp < 0.05 vs aclidinium; CI, confidence interval; COPD, chronic
obstructive pulmonary disease; EXACT; EXAcerbations of Chronic
pulmonary disease Tool; FDC, aclidinium/formoterol fixed-dose
combination; HCRU, Healthcare Resource Utilisation; ITT, intent-to-
treat; LS, least squares; RR, rate ratio





400 μg (n = 722)
Formoterol
12 μg (n = 716)





0.72 (0.53, 0.97)* 0.86 (0.64, 1.14) 0.94 (0.71, 1.25)
HR vs aclidinium
(95 % CI)
0.84 (0.63, 1.12) - -
HR vs formoterol
(95 % CI)
0.77 (0.58, 1.01) - -






0.70 (0.51, 0.96)* 0.84 (0.62, 1.14) 0.90 (0.67, 1.22)
HR vs aclidinium
(95 % CI)
0.83 (0.61, 1.13) - -
HR vs formoterol
(95 % CI)
0.77 (0.57, 1.05) - -





0.79 (0.65, 0.95)* 0.92 (0.76, 1.10) 0.85 (0.71, 1.03)
HR vs aclidinium
(95 % CI)
0.86 (0.72, 1.03) - -
HR vs formoterol
(95 % CI)
0.92 (0.77, 1.10) - -
Data are for the pooled ITT-exacerbations population
CI confidence interval, COPD chronic obstructive pulmonary disease,
EXACT EXAcerbations of Chronic obstructive pulmonary disease Tool,
FDC aclidinium/formoterol fixed-dose combination, HCRU Healthcare Resource
Utilisation, HR hazard ratio, ITT intent-to-treat
*p < 0.05 vs placebo
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morning symptom scores ranged from 1.1 to 1.3 units,
compared with 1.9 to 2.4 units in the Beier et al. aclidi-
nium monotherapy study (mean % predicted FEV1:
55.5–56.0) [35] and mean baseline E-RS total scoreranged from 12.2 to 12.9 units compared with 12.5 to
18.2 units in other clinical studies (mean % predicted
FEV1: 42.2–58.8) [27]. Although statistically significant
improvements in these endpoints were observed versus
placebo and monotherapy, low baseline scores may
have reduced the opportunity to demonstrate benefit in
terms of the magnitude of treatment effect.
It is not possible to draw definitive conclusions from
comparisons between different studies with LAMA/LABA
combinations given the limited data available and differ-
ences in study designs and the methods used to assess
symptoms. However, in the SHINE study, improve-
ments in the percentage of nights with no awakenings
were reported with indacaterol/glycopyrronium 110/
50 μg compared with placebo and glycopyrronium, as
well as significant increases in the percentage of days
with no daytime symptoms compared with placebo and
the percentage of days patients were able to perform
Bateman et al. Respiratory Research  (2015) 16:92 Page 11 of 13their usual activities compared with placebo and both
monocomponents [15]. Our results extend these find-
ings by demonstrating that aclidinium/formoterol FDC
400/12 μg can provide symptom control over a 24-hour
period, improving overall daily, night-time and early-
morning symptoms compared with placebo and the
monotherapies. Additionally, significant improvements
in limitation of early-morning activities were observed
versus placebo and both monotherapies. The symptom
control achieved over a 24-hour period with aclidinium/
formoterol FDC may be a result of its BID administra-
tion. Aclidinium monotherapy BID has been shown
to improve overall daily, night-time and early-morning
symptoms of COPD [35]. Additionally, formoterol BID
in combination with an ICS has been shown to improve
daily symptoms and reduce night-time awakenings
[36, 37]. However, head-to-head studies of once-daily
versus twice-daily LAMA/LABA combinations will be
required to address this question.
Aclidinium/formoterol FDC 400/12 μg reduced the
rate of moderate or severe HCRU exacerbations and
EXACT exacerbations of any severity versus placebo.
Additionally, the time to first HCRU (moderate or se-
vere or any severity) or EXACT exacerbation (any se-
verity) was significantly reduced with FDC 400/12 μg
compared with placebo. Importantly, this benefit was
observed in a population not selected for exacerbation
history, making the findings relevant to a wider
spectrum of patients with COPD. A previous study of a
dual bronchodilator in COPD (glycopyrronium [LAMA]
and indacaterol [LABA]; the SPARK study) reported sig-
nificant improvements in exacerbation rates with the
combination versus glycopyrronium and tiotropium alone
[38]. However, this study benefited from an enriched pa-
tient population with more severe airflow limitation
(GOLD Stage III and IV) and ≥1 moderate exacerbation
in the previous year. Further investigation of aclidinium/
formoterol FDC 400/12 μg is required in studies specific-
ally designed to assess exacerbations.
ICS are commonly prescribed in combination with
long-acting bronchodilators for the treatment of pa-
tients with COPD who are at high risk of exacerbation
[39] and it is therefore important to examine the im-
pact of ICS use on treatment outcomes. Stratification
of the data by concomitant ICS use demonstrated that
FDC 400/12 μg improves TDI by the MCID compared
with placebo, regardless of concomitant ICS use.
However, significant improvements in TDI with FDC
400/12 μg versus the monotherapy components were
only observed in patients who were not using ICS, sug-
gesting that dual bronchodilation provides additional
symptom benefit over monotherapy in such patients.
HCRU and EXACT exacerbation rates were significantly
reduced with FDC 400/12 μg compared with placebo inpatients using ICS, but not in those who were not using
ICS. However, as expected, exacerbation rates were higher
in patients who were prescribed ICS, making it easier to
demonstrate a treatment effect in these patients.
Conclusions
We have shown that a novel, BID FDC of aclidinium
and formoterol, administered over six months, signifi-
cantly improves endpoints that are important to patients
with COPD, namely, symptoms (TDI; daily, night-time
and early-morning symptoms), relief-medication use and
both reported and unreported exacerbations (moderate
or severe exacerbations measured by HCRU and exacer-
bations of any severity measured by EXACT). Improve-
ments in lung function with the FDC versus monotherapy
were expected, in line with other recent combination data.
However, pooling data from two studies of near-identical
design has allowed a more comprehensive investigation of
the benefits of the FDC in terms of symptoms and exacer-
bations. The results are consistent with the improvements
in bronchodilation observed in the individual studies and
confirm that aclidinium/formoterol FDC 400/12 μg BID
may be an effective new treatment option for patients with
moderate to severe COPD.
Endnotes
aRegistered trademark of AstraZeneca group of
companies; for use within the USA as Pressair® and
as Genuair™ within all other licensed territories.
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